Fundraising FoxSignPath Pharma
Sandy, US · Delaware corporation
Find your way into SignPath Pharma
267 people in our graph share verified history with the SignPath Pharma team — schools, employers, funds. One of them is your warm intro.
Austin Byrdunlockedknows Timothy Touloukian · together at Paulson Investment Company, LLC (overlapped)
knows the team · via Paulson Investment Company, LLC
×4knows the team · via Lenox Hill Hospital
knows the team · via Mount Sinai School of Medicine
knows the team · via Hopkins School
knows the team · via Southern Methodist University
SignPath Pharma develops small-molecule therapeutics to prevent cardiotoxicity caused by cancer treatments and other primary therapies. The company focuses on cardio-oncology, designing molecules to protect cardiac function in patients undergoing cancer therapy.
Founders & leadership
RS
Robert SegusoExecutive
PS
Peter SordilloExecutivePeter Sordillo holds an M.D. and Ph.D. in physics from NYU, and previously served as an attending oncologist and cancer researcher at Memorial Sloan-Kettering Cancer Center, where he directed clinical trials and conducted research on sarcomas and other cancers. He is Vice-President and Chief Scientific Officer at SignPath Pharma, a biotechnology company developing therapeutics for cardiac and cancer diseases.
AB
Arthur Ballon, Ph.DExecutive
TT
Timothy TouloukianExecutiveTimothy Touloukian has over 25 years of experience in investment portfolio management and capital raising for companies and institutions. He is an executive officer at SignPath Pharma, which develops small-molecule therapeutics to prevent cardiotoxicity in cancer treatment patients.
Reported raises · per SEC filings
Form D private placements$9.3M disclosed across 6 rounds · 2013–2020
▶$1.6MraisedMay 2021 · 18 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedMay 2021 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert SegusoExecutive Officer, Director
- Peter SordilloExecutive Officer
- Arthur Ballon, Ph.DExecutive Officer, Director
- Kai LarsonExecutive Officer, Director
- Timothy TouloukianExecutive Officer
- Offering amount
- $11M
- Amount sold
- $1.6M
- Minimum investment
- $6K
- Sales commissions
- $1M
- Proceeds to insiders
- $100K
- Placement agents
- Tim Touloukian
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$525KraisedAug 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$525KraisedAug 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert SegusoExecutive Officer, Director
- Timothy ToloukianExecutive Officer
- Peter SordilloExecutive Officer
- Kai LarsonExecutive Officer, Director
- Arthur P. Bollon, Ph.DDirector
- Offering amount
- $10M
- Amount sold
- $525K
- Minimum investment
- $10K
- Sales commissions
- $1M
- Proceeds to insiders
- $100K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$235KraisedDec 2017 · 4 investors · PharmaceuticalsRule 506(b)
▶$235KraisedDec 2017 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Beth HechtDirector
- Robert SagusoDirector
- Peter SordilloExecutive Officer
- Kai LarsonExecutive Officer
- Arthur P. Bollon, Ph.DDirector
- Jack Levine, CPADirector
- Offering amount
- $5M
- Amount sold
- $235K
- Minimum investment
- $100K
- Sales commissions
- $450K
- Proceeds to insiders
- $100K
- Placement agents
- John W. Stalanski
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$245KraisedJul 2016 · 8 investors · PharmaceuticalsRule 506(b)
▶$245KraisedJul 2016 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur P. Bollon, Ph.DDirector
- Kai Larson, JDExecutive Officer
- Lawrence D. HelsonExecutive Officer, Director
- None Meyers Associates, L.P.Promoter
- Jack Levine, CPADirector
- Offering amount
- $5M
- Amount sold
- $245K
- Minimum investment
- $100K
- Sales commissions
- $650K
- Proceeds to insiders
- $404K
- Placement agents
- John D. Telfer
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedJan 2016 · 36 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedJan 2016 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jack Levine, CPADirector
- Arthur P. Bollon, Ph.DDirector
- Lawrence D. HelsonExecutive Officer, Director
- None Meyers Associates, L.P.Promoter
- Offering amount
- $3M
- Amount sold
- $2.4M
- Minimum investment
- $100K
- Sales commissions
- $235.9K
- Proceeds to insiders
- $204K
- Placement agents
- Bruce Meyers
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.4MraisedJun 2014 · 14 investors · PharmaceuticalsRule 506(b)
▶$4.4MraisedJun 2014 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence D. HelsonExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $4.4M
- Minimum investment
- $100K
- Sales commissions
- $500K
- Proceeds to insiders
- $204K
- Placement agents
- Bruce Meyers
- First sale
- Mar 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Eli Lilly8 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Milestone Pharmaceuticals6 shared keywordsMilestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
Ascendis Pharma6 shared keywordsAscendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.
Solu5 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with SignPath Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does SignPath Pharma do?
- SignPath Pharma develops small-molecule therapeutics to prevent cardiotoxicity caused by cancer treatments and other primary therapies. The company focuses on cardio-oncology, designing molecules to protect cardiac function in patients undergoing cancer therapy.
- Who founded SignPath Pharma?
- SignPath Pharma was founded by Lawrence D. Helson.
- How much funding has SignPath Pharma raised?
- SignPath Pharma has disclosed $9.3M raised across 6 rounds.
- Where is SignPath Pharma headquartered?
- SignPath Pharma is headquartered in Sandy, US.